What do systematic reviews say?

Zinc vs placebo

The review found no eligible studies for this question.

• Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings – denosumab vs placebo

The review found no eligible studies for this question.

• Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Hydroxyurea vs placebo

The review found no eligible studies for this question.

• Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Angiotensin‐converting enzyme inhibitors vs placebo

The review found no eligible studies for this question.

• Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Cisapride vs placebo

The review found no eligible studies for this question.

• Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: oral β‐carotene vs placebo

The review found no eligible studies for this question.

• Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: oral vitamin E supplementation vs placebo or no treatment

The review found no eligible studies for this question.

• Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Oral magnesium pidolate vs placebo or no intervention

The review found no eligible studies for this question.

• Magnesium for treating sickle cell disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Hydroxyurea vs placebo or usual care

The review found no eligible studies for this question.

• Hydroxyurea for reducing blood transfusion in non‐transfusion dependent beta thalassaemias 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Short‐acting inhaled beta‐2 agonists vs placebo

The review found no eligible studies for this question.

• Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Short‐acting inhaled muscarinic antagonists vs placebo

The review found no eligible studies for this question.

• Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ Ciklavit® vs placebo

The review found no eligible studies for this question.

• Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ Pfaffia paniculata vs placebo

• Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 30 participants
  Very low

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ monotherapy: cavosonstat vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ monotherapy: lumacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found